Advertisement
UK markets closed
  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     
  • FTSE 250

    20,749.90
    -72.94 (-0.35%)
     
  • AIM

    794.02
    +1.52 (+0.19%)
     
  • GBP/EUR

    1.1678
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2706
    +0.0035 (+0.28%)
     
  • Bitcoin GBP

    52,829.15
    +615.79 (+1.18%)
     
  • CMC Crypto 200

    1,371.50
    -2.34 (-0.17%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.21 (+0.34%)
     
  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     
  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     
  • HANG SENG

    19,553.61
    +177.08 (+0.91%)
     
  • DAX

    18,704.42
    -34.39 (-0.18%)
     
  • CAC 40

    8,167.50
    -20.99 (-0.26%)
     

Growth Opportunities and Innovative Use Cases for AI in Clinical Trials

ReportLinker
ReportLinker

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution.

New York, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Growth Opportunities and Innovative Use Cases for AI in Clinical Trials" - https://www.reportlinker.com/p06383513/?utm_source=GNW

Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs.

The rapid adoption of AI/ML algorithms and platforms to structure and utilize electronic health records (EHRs) allows the industry to tap into a vast, rich, and highly relevant data source that holds tremendous potential in improving the global clinical trial landscape. Incorporating integrated AI-driven solutions in clinical trial design and patient retention will ease the go-to-market strategy for various CROs and pharma players as they will reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, as well as engagement through interactive platforms thus ensuring higher retention.

Additionally, these platforms are highly beneficial in the selection of appropriate investigators and trial sites.

Randomized control trials (RCTs) are another possible application for sponsors to leverage AI in analyzing vast site-level datasets for greater insight into trial design and implementation.

Leading CROs such as Syneos Health or IQVIA, as well as several pharmaceutical companies such as BMS, have successfully deployed AI-based platforms to support site selection and patient recruitment.

Companies (including AstraZeneca and Novartis among others) are also applying AI in clinical trials to enable the optimization of different stages with the intent of reducing the overall trial timelines.

AI technologies bring fundamental innovations for transforming clinical trials, such as collecting and analyzing real-world data, seamlessly combining phases I and II of clinical trials, and developing novel patient-centered endpoints.

AI can be leveraged to create standardized, structured, and digital data elements from a range of inputs, and as AI-enabled study design helps optimize and accelerate the creation of patient-centric designs, it significantly reduces patient burden, increases the likelihood of success, decreases the number of amendments, and improves the overall efficiency of trials.

Together, big technology providers and pharmaceutical start-ups are setting the course for more effective clinical trials in the future.
Read the full report: https://www.reportlinker.com/p06383513/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001